Dofetilide-induced long QT and torsades de pointes

Annals of Noninvasive Electrocardiology

Volumn 12, Issue 3, 2007, Pages 197-202

  Aktas, Mehmet K ^a   Shah, Abrar H ^a   Akiyama, Toshio ^b,c  

^a STRONG MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c Cardiovascular Sciences   (United States)

Author keywords

Atrial fibrillation; Dofetilide; Tikosyn; Torsades de pointes

Indexed keywords

ANTIARRHYTHMIC AGENT; DOFETILIDE; MILRINONE; POTASSIUM;

ADULT; AGED; ATRIOVENTRICULAR BLOCK; CASE REPORT; DEFIBRILLATOR; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; LUNG EDEMA; MALE; POTASSIUM BLOOD LEVEL; POTASSIUM CURRENT; PRIORITY JOURNAL; QRS COMPLEX; QT PROLONGATION; REVIEW; RISK FACTOR; SUPRAVENTRICULAR TACHYCARDIA; TORSADE DES POINTES;

AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; PHENETHYLAMINES; RISK FACTORS; SULFONAMIDES; TORSADES DE POINTES;

EID: 34447117577     PISSN: 1082720X     EISSN: 1542474X     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2007.00161.x     Document Type: Review

References (11)

1. Mounsey JP, DiMarco JP. Cardiovascular drugs. Dofetilide. Circulation 2000 102 : 2665 2670.
2. Falk RH, Decara JM. Dofetilide: A new pure class III antiarrhythmic agent. Am Heart J 2000 140 : 697 706.
3. Rousseau MF, Massart PE, van Eyll C, et al. Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure. Am J Cardiol 2001 87 : 1250 1254.
4. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: The symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000 102 : 2385 2390.
5. Guanzon AV, Crouch MA. Phase IV trial evaluating the effectiveness and safety of dofetilide. Ann Pharmacother 2004 38 (7 8 1142 1147.
6. Kober L, Bloch Thomsen PE, Moller M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomised trial. Lancet. 2000 356 : 2052 2058.
7. Pedersen OD, Bagger H, Keller N, Marchant B, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001 104 : 292 296.
8. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish investigations of arrhythmia and mortality on Dofetilide Study Group. N Engl J Med. 1999 341 : 857 865.
9. Tendera M, Wnuk-Wojnar AM, Kulakowski P, et al. Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: A 6-month double-blind comparison with propafenone and placebo. Am Heart J 2001 142 : 93 98.
10. Boriani G, Biffi M, Bacchi L, et al. A randomised cross-over study on the haemodynamic effects of oral dofetilide compared with oral sotalol in patients with ischaemic heart disease and sustained ventricular tachycardia. Eur J Clin Pharmacol 2002 58 : 165 169.
11. Brendorp B, Elming H, Jun L, et al. QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation. 2001 103 : 1422 1427.